Harvey David Humes, MD

Harvey David Humes, MD

Specialty: Nephrology, Internal Medicine
Title: Professor

To request an appointment call

734-615-3217
Harvey David Humes, MD
Nephrology
  • Areas of Practice
  • Locations
  • Insurance
  • Education & Training
  • Research Overview
  • Manage Your Profile

  • Areas of Practice

    Acute renal failure (ARF), cell therapy, bioartificial kidney, stem cell therapy and all aspects of general adult Nephrology, including chronic kidney disease (CKD).

    Locations

    • U of M Nephrology 1500 E Medical Center Dr
      Ann Arbor, MI 48109-5000

    Insurance Accepted

    University of Michigan Health participates with most health insurance plans.

    See our insurance details

    Education & Training

    Medical School or Training

    University of California, San Francisco, 1973

    Residency

    Moffit Hospital, Internal Medicine, 1975

    Fellowships

    University of Pennsylvania Hospital, Internal Medicine, 1976

    Board Certifications

    Internal Medicine
    Nephrology

    Professional Organizations

    Alpha Omega Alpha
    American Association for the Advancement of Science
    American Federation for Medical Research
    American Heart Association
    American Physiological Society
    American Society for Artificial Internal Organs
    American Society of Biological Chemists
    American Society of Nephrologists
    American Society of Renal Biochemistry and Metabolism
    Association of American Medical Colleges
    Association of Professors of Medicine
    Central Society for Clinical Research
    Fellow of American Academy of Pediatrics
    International Society of Nephrology
    Midwest Salt and Water Club
    National Kidney Foundation
    National Kidney Foundation of Michigan

    Research Overview

    Acute renal failure, Cell therapy, Bioartificial kidney, Stem cell therapy

    Featured News & Stories

    man showing device in his hand smiling with blue gloves on
    Health Lab

    First-of-its-kind therapeutic device saves child in septic shock with multiorgan failure

    The selective cytopheretic device, created by scientists and doctors at Michigan Medicine, is a first-in-class autologous immune cell directed therapy and successfully treated a young patient in septic shock and multiorgan failure.